AU Patent

AU2022204106A1 — Methods of treatment of acne vulgaris using topical dapsone compositions

Assigned to Allergan Inc · Expires 2022-06-30 · 4y expired

What this patent protects

Dapsone compositions can be useful for treating acne. The methods and formulations disclosed herein show efficacy for treating acne vulgaris and/or post inflammatory hyperpigmentation.

USPTO Abstract

Dapsone compositions can be useful for treating acne. The methods and formulations disclosed herein show efficacy for treating acne vulgaris and/or post inflammatory hyperpigmentation.

Drugs covered by this patent

Patent Metadata

Patent number
AU2022204106A1
Jurisdiction
AU
Classification
—
Expires
2022-06-30
Drug substance claim
No
Drug product claim
No
Assignee
Allergan Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.